GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Collegium Pharmaceutical Inc (FRA:354) » Definitions » Short-Term Debt

Collegium Pharmaceutical (FRA:354) Short-Term Debt : €61.7 Mil (As of Dec. 2024)


View and export this data going back to 2016. Start your Free Trial

What is Collegium Pharmaceutical Short-Term Debt?

Collegium Pharmaceutical's Short-Term Debt for the quarter that ended in Dec. 2024 was €61.7 Mil.

Collegium Pharmaceutical's quarterly Short-Term Debt declined from Jun. 2024 (€170.3 Mil) to Sep. 2024 (€58.2 Mil) but then increased from Sep. 2024 (€58.2 Mil) to Dec. 2024 (€61.7 Mil).

Collegium Pharmaceutical's annual Short-Term Debt increased from Dec. 2022 (€153.4 Mil) to Dec. 2023 (€168.1 Mil) but then declined from Dec. 2023 (€168.1 Mil) to Dec. 2024 (€61.7 Mil).


Collegium Pharmaceutical Short-Term Debt Historical Data

The historical data trend for Collegium Pharmaceutical's Short-Term Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Collegium Pharmaceutical Short-Term Debt Chart

Collegium Pharmaceutical Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Short-Term Debt
Get a 7-Day Free Trial Premium Member Only Premium Member Only 39.04 42.79 153.40 168.12 61.68

Collegium Pharmaceutical Quarterly Data
Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
Short-Term Debt Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 168.12 168.67 170.32 58.19 61.68

Collegium Pharmaceutical Short-Term Debt Explanation

Short-Term Debt represents the total amount of Long-Term Debt such as bank loans and commercial paper, which is due within one year.


Collegium Pharmaceutical Short-Term Debt Related Terms

Thank you for viewing the detailed overview of Collegium Pharmaceutical's Short-Term Debt provided by GuruFocus.com. Please click on the following links to see related term pages.


Collegium Pharmaceutical Business Description

Traded in Other Exchanges
Address
100 Technology Center Drive, Stoughton, MA, USA, 02072
Collegium Pharmaceutical Inc is a specialty pharmaceutical company. The company is engaged in developing and planning to commercialize abuse-deterrent products that incorporate its patented DETERx platform technology for the treatment of chronic pain and other diseases. The DETERx platform technology is designed to maintain the extended-release and safety profiles of abused drugs in the face of various methods including chewing, crushing, and dissolving. Its product portfolio includes Jornay, Xtampza ER, which is an abuse-deterrent, extended-release, oral formulation of oxycodone; and Nucynta Products, which are extended-release and immediate-release formulations of tapentadol; Belbuca, and Symproic.

Collegium Pharmaceutical Headlines

No Headlines